Navigation Links
Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
Date:4/14/2008

ns."

Dr. Liang and her colleagues reported on their study of a bavituximab equivalent antibody, 2aG4, in combination with a clinical stage small molecule agent, PRIMA-1. PRIMA-1 restores the normal function of mutant forms of the tumor suppressor p53, enabling it to induce tumor cell death. The combination therapy resulted in additive and synergistic anti-tumor effects in two mouse models of advanced breast cancer, enhancing tumor regression and elimination, while also reducing the incidence of lymph node metastases in some subjects.

Dr. Liang noted, "These results indicate that PRIMA-1 plus 2aG4 combination therapy has a complementary and potent anti-tumor activity and could define a new strategy for suppression of advanced breast cancers."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab helps mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol. One of the bavituximab breast cancer trials is currently enrolling and dosing patients and the two other trials are expected to begin shortly. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

No. 2341: Ya
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  El Camino Hospital, a leader ... is utilizing the Leaf Patient Monitoring system to help ... movement of patients susceptible to bed sores. ... 138-patient study of the system, which showed dramatic improvement ... patients regularly is the one of the most effect ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today announced ... (the generic equivalent of Zyprexa® injection), in Canada.  Olanzapine ... disturbed behaviors in patients with schizophrenia or bipolar I ... injectable drug, InnoPharma has entered into an agreement with ... will make, use, sell, market and distribute Olanzapine ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... Streamline Health Solutions, Inc. (Nasdaq: STRM ... for hospitals, announced today that two of its clients, ... North Carolina, contracted with Streamline Health to implement new ... began the beta phase of integration earlier this year, ...
... July 28, 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: ... financial results for the company,s second quarter ended June 30, ... Aug. 11, 2011. The Pacira management team will host a ... and upcoming developments on Thursday, Aug. 11, 2011 at 9 ...
Cached Medicine Technology:Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 2Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 3Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 4Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call 2
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... with the Penn's Abramson Cancer Center, will host a ... together area experts in the field of mesothelioma. September ... The conference is open to the public, and specifically ... and those who have been exposed to asbestos. , ...
(Date:7/30/2014)... 2014 WalkingSticksandCane.com has just received ... ladies will love the new European fashions and the men ... sticks and canes are from one from one of the ... the styles re unique and offer the consumer the ability ... Walking Sticks are some of the rarest and most sought ...
(Date:7/30/2014)... 30, 2014 Recently, the Kansas ... period, waiving start-up fees for hospitals and clinics ... 2014 until September 30, 2014. , Modern healthcare ... and increased complexity of digital patient information, often ... applications, and data silos. , Traditional health IT ...
(Date:7/30/2014)... The Restore My Blood Sugar review recently published ... levels can now find an amazingly successful method of reducing ... created by D. Chao and Andrew Forester who claim that ... it comes to normalizing blood sugar levels. Chao actually is ... to the cure of diabetes that all patients should find ...
(Date:7/30/2014)... Land, TX (PRWEB) July 30, 2014 New ... recently announced their plans to move to a new facility. ... announced, but they will be moving soon. , MedX Pharmacy ... W Broadway in Pearland, TX 77581. This is the old ... their current one and will include a drive thru for ...
Breaking Medicine News(10 mins):Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Kansas Health Image Exchange Announces Open Enrollment; Virtual CD from Offsite Image Solves Problems with Unreadable Patient Images, Delayed Diagnosis 2Health News:Kansas Health Image Exchange Announces Open Enrollment; Virtual CD from Offsite Image Solves Problems with Unreadable Patient Images, Delayed Diagnosis 3Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:MedX Pharmacy Relocates to New Facility 2
... , HERNDON, Va., Dec. ... it has filed an Investigational New Drug (IND) application with the ... progesterone infusion product. , In September of this year, the company ... ( www.synapse-trial.com ) in early 2010 to evaluate the safety and ...
... , CINCINNATI and JACKSONVILLE, Fla., Dec. 8 LCA-Vision ... correction services under the Lasik Plus ® brand, announced today that ... free Lasik Plus® corrective vision surgery to U.S. military veterans ... Warrior Project, and is doing its part to enhance the lives ...
... DIEGO, Dec. 8 PROVERI, Inc. is pleased to ... annual New England Venture Summit Top Innovator award by youngStartup Ventures. ... a leading role in innovation for the Technology, Life Sciences and ... President and Chief Executive Officer of PROVERI, Inc., will present the ...
... , ANN ARBOR, Mich., Dec. 8 Accuri Cytometers ... systems, today announced the 2009 recipients of its Accuri Flow ... Flow Cytometer® System each year to two sets of researchers, ... innovative uses of flow cytometry. Explicitly designed for routine ...
... ... challenges in both structural reform and unavailability of resources as the ... ,non-working, age. This calls for the introduction of new schemes in ... the growing ageing population. The involvement of Information and Communication Technology ...
... ... Cavendish Street, the UK’s premier centre for Integrated Medicine, launches Regenerus, the most comprehensive ... ... the UK Health Secretary, Andy Burnham, published the results of a Department of Health ...
Cached Medicine News:Health News:BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment 2Health News:LCA-Vision Joins Forces With the Wounded Warrior Project to Give the Gift of Enhanced Vision to Wounded American Heroes 2Health News:PROVERI, Inc. Named a Top Innovator Winner 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: